![]() | |
Clinical data | |
---|---|
Other names | 1-(4-methyl-3-oxo-4-aza-5-alpha-androstane-17-beta-carbonyl)-1,3- diisopropylurea |
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C27H45N3O3 |
Molar mass | 459.675 g·mol−1 |
3D model ( JSmol) | |
| |
|
Turosteride (FCE-26,073) is a selective inhibitor of the enzyme 5α-reductase which was under investigation by GlaxoSmithKline for the treatment of benign prostatic hyperplasia (BPH), but was never marketed. [1] [2] [3] Similarly to finasteride, turosteride is selective for the type II isoform of 5α-redcutase, with about 15-fold selectivity for it over type I isoform of the enzyme. [4] [5] In animal studies it has been shown to inhibit prostate size and retard tumor growth. [2] [3] [6] [7] It may also be useful for the treatment of acne and hair loss. [8]
![]() | |
Clinical data | |
---|---|
Other names | 1-(4-methyl-3-oxo-4-aza-5-alpha-androstane-17-beta-carbonyl)-1,3- diisopropylurea |
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C27H45N3O3 |
Molar mass | 459.675 g·mol−1 |
3D model ( JSmol) | |
| |
|
Turosteride (FCE-26,073) is a selective inhibitor of the enzyme 5α-reductase which was under investigation by GlaxoSmithKline for the treatment of benign prostatic hyperplasia (BPH), but was never marketed. [1] [2] [3] Similarly to finasteride, turosteride is selective for the type II isoform of 5α-redcutase, with about 15-fold selectivity for it over type I isoform of the enzyme. [4] [5] In animal studies it has been shown to inhibit prostate size and retard tumor growth. [2] [3] [6] [7] It may also be useful for the treatment of acne and hair loss. [8]